Shahbazi Hamed 4

What Happened

• Director Hamed Shahbazi was granted a derivative award covering 31,746 shares of Niagen Bioscience (transaction reported 2026-06-26 for activity on 2026-06-24). The filing reports the acquisition price as $0.00 because this is an option/award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (timely filing).
• Transaction type/code: A (award/grant of a derivative security).
• Shares/units involved: 31,746 (reported at $0.00 for the acquisition).
• Vesting: Option vests 100% on 2027-06-24 (per footnote).
• Shares owned after transaction: not specified in the filing.
• Exercise price: not listed on the provided summary of the Form 4; the filing reports a derivative grant but does not show an exercise price here.

Context

• This was a grant of a derivative (likely stock options) that vests in one year — not an immediate sale or purchase of common shares. Option grants are typically compensation-related and do not represent an immediate market purchase or sale. If and when exercised, any future purchase cost and tax consequences will depend on the option’s exercise price and timing.